GASC1-Adapted Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Prospective Clinical Biomarker Trial

Table 1

Patient characteristics in baseline.

Characteristics	GASC1
	High (n = 24, %)	Low (n = 36, %)	Total (n = 60)
Age (year)
High (≥65)	5 (20.8)	15 (41.7)	20	0.08
Low (<65)	19 (79.2)	21 (58.3)	40
Gender
Male	13 (54.2)	24 (66.7)	37	0.24
Female	11 (45.8)	12 (33.3)	23
Tumor location
Upper-esophagus	5 (20.8)	6 (16.7)	11	0.731
Middle-esophagus	12 (50)	16 (44.4)	28
Lower-esophagus	7 (29.2)	14 (38.9)	21
cT
T1b	2 (8.3)	8 (22.2)	10	0.16
T2	2 (8.3)	12 (33.3)	14
T3	10 (41.2)	10 (27.8)	20
T4a	10 (41.2)	6 (16.7)	16
cN
N0	7 (29.2)	22 (61.1)	29	0.015
N^+	17 (70.8)	14 (38.9)	31
Clinical stage
II	4 (16.7)	22 (61.1)	26	0.001
III	17 (70.8)	10 (27.8)	27
IVA	3 (12.5)	4 (11.1)	7
Pathological grade
G1	4 (16.7)	16 (44.4)	20	0.004
G2	10 (41.7)	17 (47.2)	27
G3	10 (41.7)	3 (8.3)	13